An Integrative Perspective From an integrative perspective, lets remember that GLP-1 medications are just one tool, and they do come with side effects and important considerations
In September 2025, clinical research was published on weight loss for two oral incretin therapies: an oral version of semaglutide and Orforglipron, also a GLP-1 receptor agonist
(PubMed) Collins R, Peto R, Armitage J
The data primarily assessed were the type of study, the language of each paper, the number of patients enrolled, mean age of patients, methenamine dosage, which antibiotic was used and each dose, the duration of follow-up, and all the outcomes previously mentioned